Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine

Clinica Chimica Acta

Volumn 419, Issue , 2013, Pages 127-131

  Obayashi, Konen ^a   Tasaki, Masayoshi ^b   Jono, Hirofumi ^a   Ueda, Mitsuharu ^b   Shinriki, Satoru ^a   Misumi, Yohei ^b   Yamashita, Taro ^b   Oshima, Toshinori ^b   Nakamura, Teruya ^c   Ikemizu, Shinji ^c   Anan, Intissar ^d   Suhr, Ole ^d   Ando, Yukio ^b  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibody against amyloidogenic transthyretin V30M; Familial amyloidotic polyneuropathy; Phenotype; Transthyretin

Indexed keywords

EPITOPE; METHIONINE; PREALBUMIN; VALINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUP; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; GENE MUTATION; HUMAN; JAPANESE; MALE; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SWEDISH; WILD TYPE;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; ANTIBODIES; ANTIGEN-ANTIBODY REACTIONS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; JAPAN; MALE; MASS SPECTROMETRY; PHENOTYPE; PREALBUMIN; SWEDEN;

EID: 84875244684     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.02.002     Document Type: Article

References (31)

1. Dwulet F.E., Benson M.D. Polymorphism of human plasma thyroxin binding prealbumin. Biochem Biophys Res Commun 1983, 114:657-662.
2. Araki S. Type I familial amyloidotic polyneuropathy (Japanese type). Brain Dev 1984, 6:128-133.
3. Sipe J.D., Benson M.D., Buxbaum J.N., et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012, 19:167-170.
4. Tawara S., Nakazato M., Kangawa K., Matsuo H., Araki S. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 1983, 116:880-888.
5. Sousa A., Andersson R., Drugge U., Holmgren G., Sandgren O. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 1993, 43:288-294.
6. Sousa A., Coelho T., Barros J., Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995, 60:512-521.
7. Ando Y., Nakamura M., Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005, 62:1057-1062.
8. Sobue G., Koike H., Misu K., et al. Clinicopathologic and genetic features of early- and late-onset FAP type I (FAP ATTR Val30Met) in Japan. Amyloid 2003, 10(Suppl. 1):32-38.
9. Miroy G.J., Lai Z., Lashuel H.A., Peterson S.A., Strang C., Kelly J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A 1996, 93:15051-15056.
10. Palha J.A., Moreira P., Olofsson A., Lundgren E., Saraiva M.J. Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy. J Mol Med (Berl) 2001, 78:703-707.
11. Ando Y., Terazaki H., Haraoka K., et al. Presence of autoantibody against ATTR Val30Met after sequential liver transplantation. Transplantation 2002, 73:751-755.
12. Ueda M., Misumi Y., Mizuguchi M., et al. SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem 2009, 55:1223-1227.
13. Goldsteins G., Persson H., Andersson K., Olofsson A., Dacklin I. Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proc Natl Acad Sci U S A 1999, 96:3108-3113.
14. Planté-Bordeneuve V., Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011, 10:1086-1097.
15. Nakazato M., Kurihara T., Matsukura S., Kangawa K., Matsuo H. Diagnostic radioimmunoassay for familial amyloidotic polyneuropathy before clinical onset. J Clin Invest 1986, 77:1699-1703.
16. Sohn J.H., So J.O., Hong H.J., et al. Identification of autoantibody against beta-amyloid peptide in the serum of elderly. Front Biosci 2009, 14:3879-3883.
17. Koike H., Misu K., Ikeda S., et al. Study Group for Hereditary Neuropathy in Japan: type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 2002, 59:1771-1776.
18. Obayashi K., Ueda M., Oshima T., et al. Pathological changes long after liver transplantation in a familial amyloidotic polyneuropathy patient. BMJ Case Rep 2012, [2012006593].
19. Yamashita T., Ando Y., Okamoto S., et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012, 78:637-643.
20. Okamoto S., Zhao Y., Lindqvist P., et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid 2011, 18:200-205.
21. Ohya Y., Okamoto S., Tasaki M., et al. Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation. Surg Today 2011, 41:1211-1218.
22. Benson M.D., Kluve-Beckerman B., Zeldenrust S.R., et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006, 33:609-618.
23. Kurosawa T., Igarashi S., Nishizawa M., Onodera O. Selective silencing of a mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun 2005, 337:1012-1018.
24. Hayashi Y., Mori Y., Yamashita S., et al. Potential use of lactosylated dendrimer (G3)/α-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy. Mol Pharm 2012, 9:1645-1653.
25. Castaño A., Helmke S., Alvarez J., Delisle S., Maurer M.S. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail 2012, 18:315-319.
26. Berk J.L., Suhr O.B., Sekijima Y., et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid 2012, 19(Suppl. 1):37-38.
27. Ferreira N., Saraiva M.J., Almeida M.R. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models. PLoS One 2012, 7:e29933.
28. Jono H., Anno T., Motoyama K., et al. Potential use of glucuronylglucosyl-β-cyclodextrin as a novel therapeutic tool for familial amyloidotic polyneuropathy. Amyloid 2012, 19(Suppl. 1):50-52.
29. Macedo B., Batista A.R., Ferreira N., Almeida M.R., Saraiva M.J. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta 2008, 1782:517-522.
30. Terazaki H., Ando Y., Fernandes R., Yamamura K., Maeda S., Saraiva M.J. Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest 2006, 86:23-31.
31. Su Y., Jono H., Torikai M., et al. Antibody therapy for familial amyloidotic polyneuropathy. Amyloid 2012, 19(Suppl. 1):45-46.